Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Adjuvanted Trivalent Influenza Vaccine in Children in Mexico
2014-004248-36Phase 3
- Sponsor
- Novartis
- Start
- Oct 2014
- Modality
- Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of adjuvanted trivalent subunit influenza vaccine in influenza (2 arms), sponsored by Novartis. Primary endpoint: Solicited local and systemic adverse events.
02
Drugs
adjuvanted trivalent subunit influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on 2014-004248-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004248-36.